 SEATTLE, June 1, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today reported its financial results for the first quarter ended March 31, 2021. The U.S. Food and Drug Administrations FDA acceptance of our New Drug Application NDA for pacritinib with priority review and a Prescription Drug User Fee Act PDUFA action date of November 30, 2021 brings us one step closer to providing pacritinib to myelofibrosis patients with severe thrombocytopenia who are underserved by existing therapies, said Adam R. 